Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis
Abstract Background In adult patients with arthritis, use of the tumor necrosis factor (TNF) inhibitor etanercept (ETN) is often associated with a reduction in the utilization of co-medications, particularly steroids. Comparatively little is known about the utilization of co-medications when ETN is...
Saved in:
Main Authors: | Majed Khraishi (Author), Brad Millson (Author), John Woolcott (Author), Heather Jones (Author), Lisa Marshall (Author), Nicolino Ruperto (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
by: Anders Öman, et al.
Published: (2021) -
Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate
by: Ekaterina Alexeeva, et al.
Published: (2019) -
Evaluation of Efficacy and Safety of Etanercept and Etanercept + Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis without Systemic Manifestations
by: T. M. Bzarova, et al.
Published: (2016) -
No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis - a matched pair analysis
by: Schmeling Heinrike, et al.
Published: (2012) -
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
by: Tiina Levälampi, et al.
Published: (2023)